Welcome back to The State of AI, a new collaboration between the Financial Times and MIT Technology Review. Every Monday, writers from both publications debate one aspect of the generative AI revolution reshaping global power. In this week’s conversation MIT Technology Review’s senior reporter for features and investigations, Eileen Guo, and FT tech correspondent Melissa […]
J&J’s tau-targeting antibody fails Phase 2 Alzheimer’s study
Johnson & Johnson’s anti-tau monoclonal antibody failed to slow the progression of Alzheimer’s in patients with early-stage disease, marking the end of one of the company’s most promising candidates. The company said in a …
What’s next for AlphaFold: A conversation with a Google DeepMind Nobel laureate
In 2017, fresh off a PhD on theoretical chemistry, John Jumper heard rumors that Google DeepMind had moved on from building AI that played games with superhuman skill and was starting up a secret project to predict the structures of proteins. He applied for a job. Just three years later, Jumper celebrated a stunning win […]
Mobile Phone Addiction and Suicidal Behaviors in Adolescents: School-Based Cross-Sectional Study in Zhejiang Province, China
Background: Suicide is a critical public health issue in adolescents. Mobile phone addiction (MPA) is characterized by an impaired ability to use mobile phones appropriately, which may further induce addictive symptoms analogous to those of substance abuse disorders and exhibit a significant association with suicidal behaviors. However, the associations between MPA and suicidal behaviors have […]
Kelun’s TROP2 ADC plus Keytruda improves outcomes in first-line lung cancer
Merck’s partner on an experimental antibody-drug conjugate has reported a Phase 3 win in first-line lung cancer, and will take the data to Chinese regulatory authorities. Chengdu-based Kelun-Biotech said that a combination of its ADC …
Sarepta to pay $200M milestone to Arrowhead; Enlivex reports osteoarthritis data
Plus, news about Clearside Biomedical, Pfizer, Astellas, Merck, MindImmune Therapeutics and Poxel: 💵 Sarepta to pay Arrowhead $200M as it continues type 1 myotonic dystrophy study: Sarepta
Angelini rapped for criticism of EMA approval
Angelini has been rapped under the UK pharma industry’s code of practice for criticising licensing decisions made by the EMA and other breaches.
Disappointment as Novo’s oral GLP-1 fails in Alzheimer’s
GLP-1 agonists have been shown to be beneficial in a lengthening list of diseases, but it seems Alzheimer’s disease may not be among them.
Sex and age estimation from cardiac signals captured via radar using data augmentation and deep learning: a privacy concern
IntroductionElectrocardiograms (ECGs) have long served as the standard method for cardiac monitoring. While ECGs are highly accurate and widely validated, they require direct skin contact, are sensitive to motion artifacts, and are not always practical for continuous or unobtrusive monitoring, limiting their generalization to real-world, dynamic environments. However, radar-based technologies offer a novel, non-invasive alternative […]
Open LLM-based actionable incidental finding extraction from [18F]fluorodeoxyglucose PET-CT radiology reports
IntroductionWe developed an open, large language model (LLM)-based pipeline to extract actionable incidental findings (AIFs) from [18F]fluorodeoxyglucose positron emission tomography-computed tomography ([18F]FDG PET-CT) reports. This imaging modality often uncovers AIFs, which can affect a patient’s treatment. The pipeline classifies reports for the presence of AIFs, extracts the relevant sentences, and stores the results in structured […]